Ascendis Pharma A/S
NASDAQ:ASND
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ascendis Pharma A/S
NASDAQ:ASND
|
DK |
|
T
|
Tenet Healthcare Corp
F:THC1
|
US |
|
Dominion Energy Inc
NYSE:D
|
US |
|
Patterson Companies Inc
NASDAQ:PDCO
|
US |
|
U
|
Unilever PLC
VSE:ULVR
|
UK |
|
Cheesecake Factory Inc
NASDAQ:CAKE
|
US |
|
Toyota Motor Corp
TSE:7203
|
JP |
|
I
|
Ithaca Energy PLC
LSE:ITH
|
UK |
|
X
|
Xero Ltd
F:0XE
|
NZ |
|
First Nordic Metals Corp
OTC:FNMCD
|
CA |
|
C
|
Cipher Pharmaceuticals Inc
OTC:CPHRF
|
CA |
|
I
|
Investec PLC
LSE:INVR
|
UK |
|
Dabur India Ltd
NSE:DABUR
|
IN |
|
Tech Mahindra Ltd
NSE:TECHM
|
IN |
|
Kroger Co
NYSE:KR
|
US |
|
F
|
Fidelity National Information Services Inc
DUS:ZGY
|
US |
|
D'Ieteren Group NV
F:DJDA
|
BE |
|
C
|
CONSOL Energy Inc
F:C9X
|
US |
Wall St Price Targets
ASND Price Targets Summary
Ascendis Pharma A/S
According to Wall Street analysts, the average 1-year price target for
ASND is 301.58 USD with a low forecast of 258.56 USD and a high forecast of 362.25 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ASND's stock price target?
Price Target
301.58
USD
According to Wall Street analysts, the average 1-year price target for
ASND is 301.58 USD with a low forecast of 258.56 USD and a high forecast of 362.25 USD.
What is the Revenue forecast for Ascendis Pharma A/S?
Projected CAGR
23%
Over the last 12 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 23%.